Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,511.00-0.52%ETH$2,696.35-0.71%GOLD$4,192.90+0.14%OIL$89.86+0.47%
Smart Investors Daily
SID Premium
SP

NASDAQ · SPRY

ARS Pharmaceuticals, Inc.

Healthcare · Biotechnology

$4.29

Up+$0.01 (+0.12%)

Updated Oct 6, 2026, 11:27 PM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.1B
P/E ratio
-13.85
Dividend yield
0.00%
52-week range
$3.99 – $10.87
Volume
1.62M
Avg. volume
2.29M

Price performance · SPRY

SPRY price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

SPRY closed at $4.29 after 20 trading sessions, down 20.41% for the selected period.

Last close
$4.29
Period change
-20.41%
Period low
$4.07
Period high
$5.39
Daily close
View OHLC price history
SPRY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$4.13$4.395$4.03$4.291.62M
Oct 2, 2026$4.16$4.27$3.985$4.071.83M
Oct 1, 2026$4.35$4.395$4.11$4.121.97M
Sep 30, 2026$4.43$4.45$4.24$4.311.3M
Sep 29, 2026$4.11$4.435$4.01$4.401.27M
Sep 28, 2026$4.06$4.19$4.00$4.13949.89K
Sep 25, 2026$4.18$4.18$4.02$4.081.04M
Sep 24, 2026$4.21$4.24$4.07$4.151.05M
Sep 23, 2026$4.49$4.49$4.11$4.181.37M
Sep 22, 2026$4.40$4.57$4.36$4.481.27M
Sep 21, 2026$4.16$4.385$4.07$4.351.2M
Sep 18, 2026$4.10$4.20$4.10$4.111.89M
Sep 17, 2026$4.26$4.30$4.12$4.151.87M
Sep 16, 2026$4.25$4.365$4.125$4.1651.45M
Sep 15, 2026$4.50$4.50$4.2202$4.252.78M
Sep 14, 2026$4.80$4.90$4.455$4.502.17M
Sep 11, 2026$5.13$5.19$4.73$4.762.57M
Sep 10, 2026$5.20$5.22$5.02$5.061.09M
Sep 9, 2026$5.35$5.38$5.215$5.23874.55K
Sep 8, 2026$5.515$5.535$5.305$5.391.09M

Latest SPRY news

The latest Smart Investors Daily articles mentioning SPRY.

Stock researchCompany · Overview

SPRY research

Overview

Company profile and research snapshot.

Company profile

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$31.00
Implied upside
—
Analysts
—
SPRY recent ratings
DateFirmRatingTarget
Jun 25, 2026Leerink PartnersOutperform—
May 28, 2026Cantor FitzgeraldOverweight—
Sep 4, 2025Roth CapitalBuy—
Mar 7, 2025ScotiabankSector Outperform—
Jan 14, 2025Raymond JamesStrong Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 1, 2026

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to treat and prevent severe allergic reactions, today announced that Donn Casale, President and CEO, will participate in the following September investor conferences. Wells Fargo Healthcare Conference 1x1 Investor Meetings: Wednesday, September 9, 2026Location: Boston Cantor Global Healthcare Conference Fireside Chat: Fr

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By